N

Neurocrine Biosciences

Develops and markets neurology-focused therapies

Senior Director, Competitive Intelligence

Full-Time
$234.6k - $320k/yr+ 35% Target Bonus + Equity-Based Long-Term Incentive
Expert
Bachelor's, Master's, MBA, PharmD, PhD, MD
San Diego, CA, USA
In Person
Business & StrategyCorporate Strategy
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A Bachelor of Science or Bachelor of Arts degree in life sciences, business, or a related discipline and 14 or more years of relevant pharmaceutical, biotechnology, consulting, investment research, competitive intelligence, strategy, or related experience; alternatively, a master's degree or Master of Business Administration and 12 or more years of relevant experience; or a PhD, PharmD, MD, or other advanced degree and 10 or more years of relevant experience.
  • Significant experience in biopharmaceutical competitive intelligence, corporate strategy, business development, commercial strategy, consulting, investment research, or a related strategic function.
  • Deep understanding of drug discovery and development, clinical trials, regulatory pathways, and commercialization.
  • Demonstrated ability to understand complex scientific and clinical information and translate it into business and strategic implications.
  • Ability to operate across multiple therapeutic areas, mechanisms, and stages of development rather than remaining narrowly specialized in one asset or market.
  • Demonstrated hands-on proficiency with modern generative AI tools and a track record of incorporating AI into day-to-day analytical workflows.
  • Ability to demonstrate how AI can be used to conduct research, synthesize large information sets, automate repetitive workflows, and improve the quality and speed of strategic analysis.
  • Strong understanding of the limitations of AI and ability to independently validate sources, identify hallucinations or unsupported conclusions, and apply appropriate human judgment.
  • Curiosity and a demonstrated tendency to ask what information means and what happens next, rather than merely summarizing what has already happened.
  • Ability to synthesize scientific, clinical, regulatory, commercial, market access, financial, and competitive information into differentiated strategic insights and recommendations.
  • Demonstrated ability to identify emerging competitive threats, opportunities, and weak signals and assess their implications for portfolio and business strategy.
  • Experience developing competitive landscapes, scenarios, strategic assessments, and other decision-support analyses for senior and executive leadership.
  • Recognized internal thought leader with deep expertise in a discipline and the ability to apply broad business knowledge to complex and novel situations.
  • Demonstrated ability to contribute to long-term strategy, translate strategy into actionable plans, and drive outcomes across functions.
  • Strong strategic judgment and demonstrated ability to develop an independent point of view from incomplete or ambiguous information.
  • Experience supporting senior executives and influencing high-impact portfolio, investment, or commercial decisions.
  • Strong quantitative and analytical capabilities.
  • Excellent written and verbal communication skills, including the ability to communicate complex issues simply and concisely to executive audiences.
  • Strong executive presence, influence, and relationship-building skills.
  • Demonstrated ability to influence decisions without direct authority and effectively challenge assumptions at senior levels of the organization.
  • Ability to thrive in a fast-moving environment, manage competing priorities, and focus attention on issues with the greatest strategic and business impact.
  • Demonstrated ability to collaborate effectively across functions and build strong relationships with senior leaders, internal stakeholders, and external partners.
  • Strong mentoring and leadership capabilities, with the ability to develop others and lead through influence across direct and indirect teams.
Responsibilities
  • Own and lead the enterprise competitive intelligence strategy across marketed products, development-stage assets, research programs, and emerging areas of strategic interest.
  • Develop deep competitive landscapes across therapeutic areas, integrating scientific, clinical, regulatory, commercial, market access, and financial perspectives.
  • Identify emerging competitors, mechanisms, technologies, and market developments before they become consensus, and assess their potential implications for the organization.
  • Serve as a trusted thought partner to Corporate Strategy, Business Development, R&D, Commercial, Medical Affairs, and executive leadership.
  • Translate complex competitive information into clear strategic implications and recommendations rather than simply reporting developments.
  • Develop competitor- and asset-level scenarios, including likely clinical-development strategies, regulatory paths, launch timing, positioning, commercial potential, and potential competitor responses.
  • Lead competitive assessments around major catalysts, including clinical readouts, regulatory decisions, medical congresses, product launches, earnings calls, and business development transactions.
  • Develop and maintain competitive landscapes, company profiles, pipeline databases, catalyst calendars, and other decision-support tools across the portfolio.
  • Partner with Business Development and Corporate Strategy on external innovation, transaction evaluations, market landscapes, and strategic opportunity assessments.
  • Partner with R&D teams to understand emerging biology, modalities, and development strategies and identify competitive implications early in the research and development lifecycle.
  • Partner with Commercial and Medical teams to understand evolving standards of care, physician behavior, market dynamics, and competitor positioning.
  • Design and lead competitive simulations and war-gaming exercises around important clinical, regulatory, and commercial events.
  • Build an effective system for rapidly communicating material competitive developments to leadership while avoiding information overload.
  • Build an AI-native competitive intelligence capability across the portfolio, using tools to increase the breadth, speed, and depth of competitive analysis.
  • Use large language models and other AI-enabled research and analytical tools to synthesize scientific literature, clinical-trial information, regulatory documents, patents, company disclosures, medical-congress data, market research, and other structured and unstructured information.
  • Develop workflows and agents for continuous competitive monitoring, catalyst tracking, landscape development, signal detection, and synthesis of large information sets.
  • Use AI to connect information across therapeutic areas and datasets, identify weak signals and emerging patterns, generate and pressure-test hypotheses, and surface competitive developments that traditional competitive intelligence approaches may miss.
  • Evaluate and implement new AI tools and data sources that materially improve competitive intelligence capabilities.
  • Partner with Digital/IT, Legal, Compliance, and other stakeholders to ensure appropriate and responsible use of AI and external information.
  • Build strong relationships across functions and therapeutic areas and create an enterprise network for sharing competitive intelligence.
  • Influence decisions without direct authority and effectively challenge assumptions at senior levels of the organization.
  • Manage external competitive intelligence vendors and consultants while building sufficient internal capability to retain institutional knowledge and strategic judgment.
  • Recruit, develop, and mentor competitive intelligence talent as the function grows.
  • Establish standards and best practices for competitive intelligence across the organization.
  • Develop executive-level competitive updates, portfolio reviews, governance materials, and Board presentations as needed.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience leading teams and managing external partners.

About the company

N

Neurocrine Biosciences

View

Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Get referred to Neurocrine Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue jumped 39.5% to $959 million, beating estimates.
  • Neurocrine raised 2026 INGREZZA guidance to $2.825 billion-$2.875 billion after strong prescriptions.
  • NBIP-1968 entered Phase 1 in August 2026, giving Neurocrine obesity upside.

What critics are saying

  • INGREZZA faces Zydus generic litigation after the March 2025 ANDA challenge.
  • DOJ requested INGREZZA sales documents in August 2025, threatening fines or restrictions.
  • VYKAT XR drew safety alarms in August 2026 after reported deaths and hospitalizations.

What makes Neurocrine Biosciences unique

  • INGREZZA led Neurocrine's CNS franchise, with Q2 2026 sales of $716 million.
  • CRENESSITY delivered $184 million in Q2 2026, validating Neurocrine's endocrinology expansion.
  • Soleno acquisition added VYKAT XR, the only approved PWS hyperphagia therapy, in May 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

Contract Pharma
Sep 29th, 2026
Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer.

Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer. September 29, 2026 Content Marketing Editor Why This Matters: See our coverage of other industry executive team appointments and promotions here. Neurocrine Biosciences named Eiry Roberts, MD, Chief Medical Officer, returning Roberts to a post she held from 2018 to 2025. Roberts had remained linked with Neurocrine in the intervening time as a Strategic Advisor. Resulting from this appointment, Sanjay Keswani, MD, is departing Neurocrine by mutual agreement. Chief Medical Officer's resume. During her previous tenure, Roberts led indication expansion efforts for Ingrezza (valbenazine). She also spearheaded the development program that led to U.S. FDA approval of Crenessity (crinecerfont). Before joining Neurocrine, Roberts spent 26 years at Eli Lilly and Company, most notably as Vice President, Research and Development. Roberts served on the Board of Directors of Amicus Therapeutics prior to its April 2026 acquisition by BioMarin Pharmaceutical. Currently, she serves on the Board of Directors of Bausch Health Companies. Her new appointment as CMO at Neurocrine takes effect immediately. New meets familiar at Neurocrine. "I'm honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering," Roberts said. "Having remained closely connected to the company as a Strategic Advisor, I am excited about the opportunities ahead. I look forward to building on the teams' progress, advancing the portfolio, and ultimately delivering meaningful benefits for patients." "We're pleased to welcome Eiry back to the Chief Medical Officer role," Neurocrine President and CEO Kyle Gano, PhD, said. "Her deep knowledge of Neurocrine, our pipeline, and our clinical development programs provides strong continuity... Eiry's experience with our portfolio positions her well to lead our clinical development efforts. I look forward to working closely with her once again." Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

PR Newswire
Sep 28th, 2026
Neurocrine Biosciences reappoints Eiry Roberts as chief medical officer

Neurocrine Biosciences has reappointed Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr Roberts previously held the CMO position from 2018 to 2025 and has since served as a strategic adviser to the company. During her earlier tenure, Dr Roberts led indication-expansion efforts for INGREZZA and the crinecerfont development programme that resulted in FDA approval of CRENESSITY. Before joining Neurocrine in 2018, she spent 26 years at Eli Lilly and Company in senior research and development roles. By mutual agreement, Sanjay Keswani, M.D., will depart the company. CEO Kyle W. Gano noted that Dr Roberts' knowledge of Neurocrine's pipeline positions her well to lead clinical development efforts as the company advances multiple late-stage programmes.

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

InfoMed News
Aug 7th, 2026
Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist.

Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist. Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "NBIP-'1968 is designed to engage three complementary metabolic mechanisms, reflecting our commitment to exploring multiple scientific approaches to obesity." The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-'1968 in adult participants across a range of body mass index categories, including overweight and obese. Innovations in treatment by Neurocrine bioscience. NBIP-'1968 is an internally discovered, investigational long-acting triple agonist designed for once-weekly subcutaneous administration. It targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon to influence metabolic pathways involved in appetite regulation, energy balance and glycemic control. NBIP-'1968 was designed with balanced glucagon receptor activity to optimize the potential metabolic benefits of glucagon receptor activation while supporting tolerability. Neurocrine is developing NBIP-'1968 as part of a broader obesity portfolio that includes NBIP-'2118, an investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase 1 development. NBIP-'1968 is intended for use in a fixed-dose combination with NBIP-'2118. The company's obesity research also includes earlier-stage programs designed to explore complementary mechanisms and extended dosing intervals. "Advancing NBIP-'1968 into the clinic marks another important step in building our obesity portfolio," said Jude Onyia, Ph.D., Chief Scientific Officer, Neurocrine Biosciences. "Our strategy is to explore complementary and differentiated mechanisms that may improve weight loss, preserve lean mass and ultimately address the diverse needs of people living with obesity." About Obesity Obesity is a chronic disease characterized by excess body fat and is associated with serious health conditions, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis/fatty liver disease, certain cancers and osteoarthritis. It is driven by complex biological, environmental, and genetic factors - not simply lifestyle or willpower. Obesity has reached epidemic levels worldwide, affecting a significant proportion of adults and placing a substantial burden on public health systems. Despite recent advances in treatment, there remains a need for additional therapies that support safe, effective and sustainable long-term weight management. Current therapies can have challenges with respect to gastrointestinal tolerability, dose titration, and muscle loss. More news. August 7, 2026 August 6, 2026

Yahoo Finance
Jul 31st, 2026
Neurocrine Q2 revenue jumps 40% to $959M, beating estimates by 6%

Neurocrine Biosciences reported revenue of $959 million for the quarter ended June 2026, marking a 39.5% year-on-year increase. The figure surpassed the consensus estimate of $901.54 million by 6.37%. Earnings per share came in at $2.85, up from $1.06 a year earlier and beating the consensus estimate of $2.26 by 26.11%. Product sales reached $954.3 million, exceeding analyst estimates of $881.08 million. INGREZZA sales totalled $716 million, above the $628.59 million forecast, whilst CRENESSITY generated $184 million against an estimated $170.78 million. Collaboration revenue came in at $4.7 million, below the $6.02 million estimate and down 14.6% year-on-year. Shares rose 7.8% over the past month.